DALY II USA: Interim results

Zamtocabtagene autoleucel (zamto-cel) is a tandem CD20-CD19-directed non-cryopreserved chimeric antigen receptor (CAR) T-cell therapy that can be administered as a fresh product with a short apheresis-to-infusion time of 12–14 days.^1,2 The ongoing multicenter, open-label, phase II DALY II USA trial (NCT04792489) is evaluating the efficacy and safety of zamto-cel in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥2 prior lines of therapy.^1,2 A pre-planned interim analysis was conducted in 2024, with results presented by Nirav Shah at the Transplant & Cellular Therapy Meetings of ASTCT and CIBMTR (2025 Tandem Meetings) on Feb 12–15, 2025, in Honolulu, US; and the 66th American Society of Hematology Annual Meeting and Exposition, Dec 7–10, 2024, San Diego, US.^1,2

Results from this analysis suggest that zamto-cel is associated with encouraging efficacy and a manageable safety profile in this patient population.^1,2 The trial is ongoing, with plans to enroll 100 evaluable patients.  

This educational resource is independently supported by Miltenyi Biomedicine. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.